Cargando…

Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study

Background & Aims: The prognosis of hepatocellular carcinoma (HCC) remains poor and available treatment options are limited. This retrospective study evaluated the efficacy of Multiple Antigen Stimulating Cell Therapy (MASCT) as an adjuvant therapy for the treatment of HCC after curative treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yajing, Guo, Yabing, Chen, Jinzhang, Hu, Xiaoyun, Li, Xiaoshuang, Kong, Yanjun, Zhang, Xiaoyong, Zhou, Xiangjun, Liu, Li, Hou, Jinlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929083/ https://www.ncbi.nlm.nih.gov/pubmed/29721048 http://dx.doi.org/10.7150/jca.23725

Ejemplares similares

Cancer immunotherapy with multiple tumor antigen activated autologous T cells in patients with HBV related hepatocellular carcinoma
por: Han, Yanyan, et al.
Publicado: (2014)

Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy
por: Han, Yanyan, et al.
Publicado: (2017)

Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing
por: Li, Qi, et al.
Publicado: (2022)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
por: Chen, Jinzhang, et al.
Publicado: (2020)

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020)

DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the β-catenin pathway
por: Hu, Xiaoyun, et al.
Publicado: (2021)

Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma
por: Chen, Qianhui, et al.
Publicado: (2022)

A Novel Index in Hepatocellular Carcinoma Patients After Curative Hepatectomy: Albumin to Gamma-Glutamyltransferase Ratio (AGR)
por: Shen, Junyi, et al.
Publicado: (2019)

Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study
por: Yuan, Guosheng, et al.
Publicado: (2021)

The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection
por: He, Linye, et al.
Publicado: (2019)

CELLULAR IMMUNITY IN VITRO : CLONAL PROLIFERATION OF ANTIGEN-STIMULATED LYMPHOCYTES
por: Marshall, William H., et al.
Publicado: (1969)

The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
por: Chen, Zide, et al.
Publicado: (2018)

Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients
por: Wu, Li-Li, et al.
Publicado: (2016)

Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy
por: Frankul, Leana, et al.
Publicado: (2021)

Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy
por: Liang, Minfeng, et al.
Publicado: (2011)

Predicting Survival of Patients With Rectal Neuroendocrine Tumors Using Machine Learning: A SEER-Based Population Study
por: Cheng, Xiaoyun, et al.
Publicado: (2021)

Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects
por: Zhu, Xiao-Dong, et al.
Publicado: (2020)

Impact of Diabetes Mellitus on the Prognosis of Patients with Hepatocellular Carcinoma after Curative Hepatectomy
por: Wang, Yan-Yan, et al.
Publicado: (2014)

Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy
por: HASHIMOTO, RYOJI, et al.
Publicado: (2015)

The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?
por: Sun, Xuqi, et al.
Publicado: (2019)

Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
por: Obed, Aiman, et al.
Publicado: (2007)

The prognosis of hepatocellular carcinoma after curative hepatectomy in young patients
por: Ha, Sang Yun, et al.
Publicado: (2015)

Extrahepatic recurrence of hepatocellular carcinoma after curative hepatic resection
por: Byeon, Jangmoo, et al.
Publicado: (2012)

Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis
por: Elshaarawy, Omar, et al.
Publicado: (2021)

Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma
por: Zane, Kylie E, et al.
Publicado: (2022)

Advanced nonmetastatic hepatocellular carcinoma: curative surgery may be an option
por: Leclerc, Julie, et al.
Publicado: (2022)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Obesity Does Not Influence Outcomes in Hepatocellular Carcinoma Patients following Curative Hepatectomy
por: Guo, Zhe, et al.
Publicado: (2015)

Postoperative complications affect early recurrence of hepatocellular carcinoma after curative resection
por: Zhou, Yan-Ming, et al.
Publicado: (2015)

Benefits of Splenectomy and Curative Treatments for Patients with Hepatocellular Carcinoma and Portal Hypertension: a Retrospective Study
por: Pei, Youliang, et al.
Publicado: (2018)

Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
por: Liu, Wenwu, et al.
Publicado: (2018)

Model to Predict Overall Survival in Patients With Hepatocellular Carcinoma After Curative Hepatectomy
por: Zhang, Li-xiang, et al.
Publicado: (2021)

The Signaling of Cellular Senescence in Diabetic Nephropathy
por: Xiong, Yabing, et al.
Publicado: (2019)

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients
por: Yuan, Guosheng, et al.
Publicado: (2021)

Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection
por: Liu, Yuanyuan, et al.
Publicado: (2021)

Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study
por: Wang, Kunyuan, et al.
Publicado: (2021)

Adjuvant transarterial chemoembolization to improve the prognosis of hepatocellular carcinoma following curative resection
por: Kuang, Xuejun, et al.
Publicado: (2018)

Radiomics Model Based on Gadoxetic Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation
por: Zhang, Ling, et al.
Publicado: (2021)

A comprehensive curated resource for follicle stimulating hormone signaling
por: Telikicherla, Deepthi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_diick4djjmk1j7779dge7mqdvm